medical research companies in melbourne

• Footer navigation
• Art of Science
• Discovery tours
• Research Our research Finding better ways of detecting and treating a wide range of diseases, and helping our community to live long and healthy lives. Overview Diseases Areas of research Technologies Researchers and labs Collaborative centres Research facilities Clinical trials Business development and ventures
• About About WEHI Where the world’s brightest minds collaborate and innovate to make discoveries that will help us to live healthier for longer. About WEHI Contact us Our values Diversity and inclusion Reconciliation Our people Alumni Organisational structure History Awards Annual reports Strategic plan
• Careers and education Working and studying at WEHI WEHI promotes a scientific environment that emphasises innovation, collaboration and excellence. Careers Working at WEHI Scientific positions Professional positions Education Studying at WEHI PhD Honours Masters Undergraduate Clinician-scientist training Work experience Student research projects Student association Students in focus Learning Hub
• Support us +
• Ethics and integrity
• Terms of use
• Supplying to WEHI
• Feedback and complaints
• Students in focus

Help us live healthier and longer lives.

If you would like to give to a specific research program or support the work of a particular researcher, contact our fundraising team today.

You can help stop Parkinson’s disease

Explore wehi.

“There are millions of people living healthier lives today because of WEHI’s discoveries and every day we’re working on the next vital breakthrough.”

We’re shining a light on some of our most complex health issues. With the brightest scientists and advanced technologies, we’re making new discoveries to transform lives.

We’ve been making critical discoveries for more than 100 years in the fields of cancer, immune health and infection, developmental disorders and healthy ageing. Our world-class tools and technologies help turn our research into new treatments and ways to diagnose disease.

Meet the researchers uncovering new clues in the curious case of our ageing immune system.

Their new study has visualised , for the first time, how two cell types cause the thymus to lose its function and regeneration abilities over time.  

Latest discoveries & news 

• Blood cancers
• Discoveries
• News and features
• Parkinson’s disease
• Brain cancer

Before every WEHI breakthrough comes you.

Serious illness can happen to anyone at any time. WEHI is working to help find the cures and treatments that could one day save you or someone you love.

It’s vital research. And it’s only possible thanks to the generosity of our donors.

What if we could solve the most urgent health challenges of our time, faster?

Together, we can.

• Leaving a gift in your Will
• Major gifts
• Other ways to support
• Our supporters

Learn more about the diseases we research.

• Inflammatory bowel disease
• Breast cancer
• Myeloproliferative disorders

We celebrate the benefits of a diverse and inclusive workplace.

We embrace different perspectives and backgrounds to drive a more creative environment where ideas and people can flourish.

Reconciliation

• Reconciliation Action Plan
• DeadlyScience
• Employment opportunities

Diversity & inclusion

• Our diversity and inclusion program
• Women in science
• Staff and student diversity networks

Hear from our people

“If we have the support of the community for our research, then WEHI has the expertise, knowledge and ideas.”

“WEHI has a long and impressive history in data science that has made us the envy of many other medical research institutes.”

“It’s that possibility of having real impact that drives me out of bed every day.”

What’s on at WEHI

Together, we can create a brighter future.

Support our life-saving medical research today.

• Privacy Policy

By using this website, you agree to our use of cookies in accordance with our Privacy Policy and Terms of use .

Six biotech companies in Melbourne that have been making the news

Located on the southeastern coast of Australia, Melbourne is one of the leading life science hubs in the Asia Pacific region, according to a CBRE report published in 2021. With more and more investors taking an interest in the Melbourne region, this contributes to the country’s market value of $170 billion in the sector, with numerous innovative biotech companies making their mark.

The city’s expanding life science cluster saw growth by nearly 20% in 2020, at a time when the overall Asia Pacific market had dipped by 25%. The city is home to multinational companies like medtech company PolyNovo which develops polymers that treat wounds, and biopharma company Clinuvel, which specializes in metabolic and acute disorders. Other global companies like Thermo Fisher, Johnson & Johnson and Pfizer operate in Melbourne too.

In this article, let us take a look at six biotech companies that have received funding over the past two years, to help strengthen their pipelines, commercialize their drugs and advance their technologies.

Table of contents

Nutromics is one among Melbourne’s biotech companies that secured funding this year. Having bagged A$11 million ($7 million) in pre-series funding, it looks to commercialize its continuous diagnostic monitoring technology, which is the world’s first precision diagnostic platform, in the next few years. 

With an aim to accelerate diagnostics in the clinic by integrating biotech and software technology, it has developed a skin patch device that contains DNA-based sensors that are coated onto the surface of minimally invasive microneedles. One patch can have dozens of sensors since each microneedle is a separate sensor. This lab-on-a-patch can help track various targets like biomarkers in the body continuously and in real time. The synthetic DNA strand remains unfolded until it spots its target, after which it changes shape, which the software decodes to identify the presence and the amount of the target. The patch is being designed to integrate with the clinical system, to be able to project the result on screens.

As lab diagnostics can only provide a single data point from a blood test that was taken many hours prior, which accounts for 70% of clinical decisions. According to a study published in the National Library of Medicine, it may lead to poor patient outcomes. Nutromics aims to tackle this issue with the help of its technology.

The biotech, which was established in 2017, had raked in funds worth $14 million, in another fundraising in September last year. The company’s technology is currently being tested in clinical trials at Monash University in Melbourne.

Ena Respiratory

Melbourne-based biotech company Ena Respiratory was awarded $4.38 million from the U.S. Department of Defense (DoD) to speed up the development of its lead drug candidate INNA-051, earlier this year.

Specializing in the field of innate immune modulators, the company’s candidate is a nasal spray that is being designed to target respiratory viral infections in people who do not respond well to vaccinations due to immunosuppression, and those who have a higher risk of being exposed to viral diseases. These include patients with asthma, chronic obstructive pulmonary disease (COPD), diabetes, congestive heart failure, chronic kidney disease and patients with comorbidities.

Suggested Articles

Six norwegian companies leading the country’s biotech scene, 10 universities around the world to study biotech you should know about, five orthobiologics companies leading the way in the field, ten gift ideas for a biotech enthusiast this holiday season, five recent advancements in ovarian cancer research over the past year.

INNA-05, a synthetic pegylated TLR2/6 agonist, aims to boost the body’s immune system. While the body’s natural defense system fights viruses and other pathogens, this mechanism is subdued in people with chronic respiratory diseases. So, the drug candidate works by activating TLR2 receptors in lung cells, which enables the immune system, particularly macrophages, to combat the virus. 

INNA-051 was found to have improved respiratory virus clearance as well as reduced the duration of infection in a phase 2a clinical study . Ena Respiratory plans to conduct a phase 2b study soon.

Committed to bringing cellular medicines to the forefront of treating ​​inflammatory conditions, Melbourne-based Mesoblast’s drug candidate, remestemcel-L, is currently in phase 3 trials for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD) as well as moderate to severe acute respiratory distress syndrome (ARDS). It is also developing Rexlemesocel-L, which is being investigated as a treatment for heart failure and chronic lower back pain.

Mesoblast’s cell therapies include mesenchymal lineage cells that have been taken from healthy donors, and expanded to a reproducible cell population for scale-up purposes. One of the advantages of these cells is that they can be given to patients without them undergoing donor-recipient matching.

Also in its pipeline is MPC-300-IV, a potential treatment for diabetic nephropathy and rheumatoid arthritis (RA), which is in phase 2 trials at the moment. MPC-300-IV is made up of 300 million mesenchymal precursor cells (MPCs) that are delivered to patients intravenously. It works by inhibiting proinflammatory pathways – like TNF-alpha, IL-6 and IL-17 – in both cases. 

The Melbourne-based biotech company’s remestemcel-L for treating children under the age of 12 who have been diagnosed with SR-aGVHD was rejected by the U.S. Food and Drug Administration (FDA), which demanded additional data, earlier this year. However, it aims to pour the U.S. $40 million that it received in a private placement in April, into launching remestemcel-L, as well as proceeding with a confirmatory phase 3 clinical trial of rexlemestrocel-L in patients with chronic lower back pain.

Telix Pharmaceuticals

The radiopharmaceuticals market was valued at 5.2 billion in 2022, which is forecasted to double by 2030, according to Vantage Market Research. Telix Pharmaceuticals is among the many that contribute to this market.

With a mission to advance precision care, the company has a pipeline that is based on molecularly targeted radiation, which aims to surpass the effectiveness of radiotherapies as they have a more reputable safety profile. Its Gallium 68 radioisotope small molecule for the treatment of prostate cancer, is a diagnostic imaging tool that is currently on the market. Its Lutetium 177 prostate cancer therapeutic agent is in phase 2 trials at the moment. Moreover, its theranostic candidates that target the brain and kidney are in phase 3 and phase 2 trials as well.

Additionally, according to interim data that was published earlier this month, its radio-antibody drug conjugate (rADC) investigational therapy, TLX591, was found to be safe and tolerable, after patients with prostate cancer were administered two doses that were two weeks apart, along with standard of care.

The Melbourne-based biotech company’s imaging kit for prostate cancer, Illuccix, was approved by the Australian Therapeutic Goods Administration (TGA), the U.S. Food and Drug Administration (FDA), and Health Canada, which has led to its commercialization in the U.S., Australia and New Zealand. 

Telix had raised $175 million to advance its pipeline towards commercialization, last year.

Founded in 2015 in Melbourne, clinical-stage biotech company Aravax is dedicated to developing a disease-modifying treatment for peanut allergy. 

Its drug candidate PVX108, is an immunotherapy that aims to reset immune balance among Treg cells and Th2 cells, regulatory and proinflammatory T cells that tend to be present in varied, unbalanced amounts in the case of allergies. Excess Th2 accumulates in the body and triggers other cells in a cascade of reactions, inducing allergic symptoms that include inflammation, bronchoconstriction – the tightening of muscles in the lungs making it hard to breathe – vomiting and hives.  

PVX108, which consists of peptides, is designed to target these T cells. These peptides, which are not big enough to cause an allergic reaction, are presented to T cells. They help turn off Th2 cells and activate Treg cells. This helps dampen the allergic reaction in the body.

For PVX108’s further progress in clinical trials, the company raised $20 million in a series B round last year in December. The drug candidate is being studied in a double-blind, randomized phase 2 trial in adolescents and children with peanut allergies. It received the FDA nod for its investigational new drug (IND) application last year.

Propanc Biopharma

Epithelial mesenchymal transition (EMT) is a process that causes epithelial cancer cells to spread and metastasize. Cancer therapy company Propanc Biopharma is developing a technology that is based on pancreatic proenzyme therapy that targets the EMT mechanism to kill cancer cells.

Pancreatic enzymes, which help digest proteins and fats, are known to be a primary defense against pancreatic cancer. As proenzymes suppress pathways that lead to EMT, Propanc’s proenzyme therapy aims to weaken the structure of cancer cells by converting the protein actin from its globular to its filamentous form. This leads to the collapse of the structure, thereby triggering cell death. 

Based on this technology, the company has two drug candidates in its pipeline. PRP and POP1 are presently in preclinical and research stages. PRP is derived from two proenzymes trypsinogen and chymotrypsinogen – precursors to enzymes that help break proteins down – which aids in the suppression of metastasis and tumor relapse, while having minimal toxic effects on the body. With the goal to bring PRP to the market, Propanc believes that it could be used in hospitals as preventative care for at-risk patients, as well as to manage early-stage tumors. PRP will soon be taken to the clinic for first-in-human trials in patients with advanced solid tumors, which will be held at Peter Mac Cancer Center in Melbourne.

The Melbourne-based biotech company has raised a total of $150,000 since its launch in 2007, out of which it recently obtained $120,000 in a debt financing round. 

Fostering Melbourne’s biotech companies: the impact of the bioincubator

With a growing biotech industry looking to increase research and development, Melbourne now accommodates a bioincubator that aims to boost R&D in early-stage biotech companies. It is set to open its doors to these budding companies next year. The incubator is a collaboration between biotech giant CSL, the Walter and Eliza Hall Institute of Medical Research and the University of Melbourne, to help provide technical support to startups, in an effort to cut costs for these young companies. Initiatives like this can further grow Melbourne’s biotech industry, enabling it to become a stronger contender in the field, not only in Australia and the Asia Pacific region, but also on a global scale.

Latest Articles

How to negotiate your job offer in biotech, how to succeed as a woman in biotech, the biggest private biotech investments in october 2024, cystic fibrosis: five biotechs breathing life into the therapeutic space .

Research Organisations

Comprising of more than 13 major medical research institutes, eleven teaching hospitals and nine universities, Victoria is home to Australia’s largest bioscience research community.

A number of well-known national and international research organisations are based in Victoria.

Medical Research Organisations in Victoria

Australian Genome Research Facility – is an efficient state-of-the-art facility for the collection of molecular genetic information covering large-scale DNA sequencing, genotyping, microarraying, agricultural genomic services and other resources for the genetic and physical mapping of chromosomes, mutation detection and associated bioinformatic analysis.

Baker IDI Heart and Diabetes Institute  – tackles the deadly trio of obesity, diabetes and cardiovascular disease through research, education and patient care.

Bio21 Institute for Molecular Science & Biotechnology – is a multidisciplinary research centre, specialising in medical, agricultural and environmental biotechnology.

Bionics Institute – is an independent, non-profit, medical research organisation.

Burnet Institute – The Burnet Institute is a leading Australian medical research and public health organisation focused on improving the health of disadvantaged and marginalised groups.

Centre for Eye Research Australia – The Centre brings together a body of dedicated medical researchers to improve the living conditions and lifestyles of thousands of people both in Australia and abroad who are now, or may in the future, be affected by vision impairment.

Epworth Research Institute – Epworth Research Institute (ERI) has built a reputation as a high quality medical research institute within the private teaching hospital environment.  It fosters a vibrant research culture that is committed to excellence and values clinically relevant research that translates into better outcomes for patients here and around the world.

European Molecular Biology Laboratory  – EMBL Australia was launched on 29th March 2010, making Australia the first Associate Member of EMBL. EMBL Australia provides Australian researchers access to EMBL through activities such as funded research positions, collaborative ventures and the formation of research institutes.

Institute for Breathing and Sleep – The Institute for Breathing and Sleep (IBAS) is an incorporated not-for-profit organisation designed to facilitate and coordinate research, education and public advocacy in respiratory and sleep health.

Institute for Safety, Compensation and Recovery Research – Established in April 2009, the Institute for Safety, Compensation and Recovery Research (ISCRR) is a joint initiative of WorkSafe Victoria, the Transport Accident Commission (TAC) and Monash University.

Ludwig Institute for Cancer Research – is a worldwide network of nine branches in seven countries dedicated to basic and clinical cancer research.

Mental Health Research Institute – mission is to further knowledge in mental health, behaviour and neuroscience.

Monash Institute of Medical Research – is committed to excellence in the performance of medical and biological research into the science of reproduction, development and growth.

Murdoch Childrens Research Institute (MCRI) – conducts life-saving medical research and community health research for babies, children and adolescents.

National Ageing Research Institute Inc. – strives to be the centre of excellence in medical research (biological, clinical and service delivery) into the causes and consequences of ageing and its social accompaniments.

National Health and Medical Research Council (NHMRC)  – Supporting health and medical research.

National Trauma Research Institute – The NTRI aims to prevent or limit the disabling effects of traumatic injuries through research and education in trauma care. National Vision Research Institute  – Founded in 1972, NVRI pursues research in vision and the disorders of vision.

O’Brien Institute of Microsurgery – The Institute has made striking advances in the delicate craft of replantation surgery and the transfer by microsurgical techniques of body parts and tissue to reconstruct people maimed by trauma, cancer, burns and congenital deformity.

Orygen Youth Health  – Orygen Youth Health Research Centre (OYH-RC) is Australia’s largest youth mental health research centre. Our research aims to understand the biological, psychological and social factors that influence mental illnesses in order to find better ways to prevent and/or reduce the impact of mental disorders for young people.

Peter MacCallum Cancer Centre – a premier resource for cancer patients in the provision of integrated treatment, research and education.

Prince Henry’s Institute of Medical Research – has maintained a reputation for excellence in the field of endocrinology (the study of hormones).

St Vincent’s Institute of Medical Research – an enviable reputation within the global scientific community as one of the world’s premier medical research institutes, and is a shining example of Australian intellectual excellence and achievement.

Walter and Eliza Hall Institute of Medical Research – is one of Australia’s foremost medical research establishments, its mission being “mastery of disease through discovery”.

Teaching Hospitals in Victoria

The Alfred – Alfred Health is a leader in health care delivery, improvement, research and education. We strive to achieve the best possible health outcomes for our patients and our community by integrating clinical practice with research and education.

Austin Health – Austin Health is the major provider of tertiary health services, health professional education and research in the northeast of Melbourne. Austin Health is world-renowned for its research and specialist work in cancer, liver transplantation, spinal cord injuries, neurology, endocrinology, mental health and rehabilitation.

Barwon Health (Geelong Hospital) – The Geelong Hospital has a full suite of medical and surgical services, including cardiothoracic surgery and is one of the busiest hospitals in the state. It is a 406 bed general medical and surgical teaching hospital affiliated with The University of Melbourne and Deakin University with obstetric, paediatric and psychiatric beds.

Monash Medical Centre – Monash Medical Centre Clayton is a 640 bed teaching and research hospital of international standing providing a comprehensive range of specialist surgical, medical, allied health and mental health services to our community.

Peter MacCallum Cancer Centre – Peter MacCallum Cancer Centre is a world leader in cancer treatment, research and education. At Peter Mac we treat more cancer patients each year than any other hospital and our highly skilled medical, nursing and allied health team is backed by the largest cancer research group in Australia.

Royal Children’s Hospital – As the major paediatric hospital in Victoria, the Royal Children’s Hospital provides clinical, academic and advocacy services for children and young people throughout the state. It is internationally recognised as a leading centre for research and education. In its role as a leading paediatric teaching centre, the hospital has affiliations with the University of Melbourne and LaTrobe University and links with other universities in post graduate studies.

Royal Melbourne Hospital – The Royal Melbourne Hospital is one of Victoria’s leading public teaching hospitals, and operates across two campuses. The Royal Melbourne Hospital is a privileged member of Melbourne’s world-leading Parkville Precinct, and enjoys strong relationships with many of the city’s major universities and research institutes.

Royal Women’s Hospital – The Royal Women’s Hospital is Australia’s largest specialist obstetric, gynaecological and neonatal paediatric hospital. We have an outstanding international reputation for research advances and clinical developments.

Royal Victorian Eye and Ear – Proudly serving Victorians since 1863, the Royal Victorian Eye and Ear Hospital is a state-wide teaching, training and research health service. Specialising in eye, ear, nose and throat (ENT) medicine, it is Australia’s pre-eminent specialty eye and ear hospital.

St Vincent ’s Health – Education is one of the three core roles of St. Vincent’s, along with patient care and research. Most senior staff play an active role in teaching and training. A number of our senior staff hold professorial appointments with the University of Melbourne. While educating health professionals is a priority, St. Vincent’s supports staff at all levels to complete further study and training in their field of expertise.

Western Hospital – Western Health aims to provide work based education and training for Western Health staff and students which will support excellence in practice and career progression opportunity. Some of our training programs are also available as open programs for members of the health and local community.

Universities

Deakin University – By 2012, Deakin aims to have improved its research performance so that it is in the top third of the Australian higher education sector. The staff of Deakin University are responsible for its success. Their dedication to our students, to the research we conduct and to the communities we serve, will ensure the continued success of Deakin University.

Federation University Australia  – Federation University Australia is an institution that combines teaching and research and especially one where teaching is informed by research. The university has moved, in a comparatively short period of time, to being research active. This is a credit to the University’s leaders, the staff and the students. The quest is now to increase the University’s comparative performance. The University continues to focus its research in those areas that both serve and benefit the region and the Institute for Regional and Rural Research and Innovation (IRRRI) leads that focus through its designated research centres.

La Trobe University – La Trobe’s research strategy encourages innovation, specialisation and collaboration. La Trobe is affiliated with the Biosciences Research Centre, the CRC for Plant Biosecurity, the CRC for Molecular Plant Breeding, the Bushfire Cooperative Research Centre, the Centre for Sustainable Regional Communities, as well as Departments/Programs including Botany and Zoology.

Monash University – Monash University is committed to finding solutions for 21st Century challenges such as climate change, water shortage, cancer, diabetes, obesity and those posed by terrorism. With campuses and partnerships in Australia and overseas, Monash pursues knowledge and solutions from a global perspective.

RMIT University – We focus on applied research that is delivered in partnership with leading organisations and individuals who are capable of using research outcomes to create products and services that are leading edge. The passion, energy and intellect of our researchers is used to make a difference to the economic, social, environmental and cultural well-being of the communities we operate within here in Australia and internationally through innovative research and research excellence.

Swinburne University of Technology – A commitment to high quality, high impact research is ingrained in Swinburne University. Swinburne has made remarkable progress in research and intends to continue to foster its various areas of research focus – on its way to becoming an internationally respected research-intensive University of Technology. Swinburne actively encourages and values its international and industry connections and recognises that it is this that enriches and enhances the research efforts and careers of our academic staff and students alike.

University of Melbourne – The University of Melbourne is Australia’s second largest research organisation after the CSIRO. The Melbourne Research Office and the School of Graduate Studies are the two major central academic support groups which facilitate the responsible conduct of research through educational, preventive, and service activities.

Victoria University – At Victoria University we provide quality research training, and undertake specialised and cross-disciplinary research that is recognised in Australia and overseas. Our staff and research students are part of an innovative research community made up of University institutes, research centres and faculty research units that make a substantial contribution in their field. We actively pursue opportunities to collaborate with other researchers and organisations to develop innovative technologies that can also be commercialised and transferred for use by business, industry and the broader community.

NHMRC Centres of Clinical Research Excellence (CCREs)

Diabetes CCRE – Based at the University of Melbourne, the Diabetes CCRE seeks to encourage and promote clinical research in diabetes and its complications, with the ultimate goal of improving the treatment and prevention of this disease.

CCRE for Translational Clinical Research in Major Eye Diseases  – This CCRE will fund a world-leading, broad-based, clinical and translational research program in Melbourne and Sydney to tackle the four eye diseases that cause the majority of vision loss in Australia: age-related macular degeneration, diabetic retinopathy, cataract and glaucoma eye diseases. The CCRE will be headquartered at the Centre for Eye Research Australia in Victoria.

CCRE in Newborn Medicine  – Based at the Murdoch Childrens Research Institute, the CCRE in Newborn Medicine will study adverse outcomes for the brains and lungs of newborn babies.

Biosciences Research Centre – AgriBio, the Centre for AgriBioscience.

The Victorian Government, through the Department of Primary Industries (DPI), and La Trobe University (La Trobe) are investing in a world-class centre for agricultural biosciences research and development through a AUD$288 million public-private partnership.

The building will be known as AgriBio, the Centre for AgriBioscience . AgriBio will focus on cutting-edge research to improve productivity, fight disease and reduce environmental impact, to protect Victoria’s $11.8 billion agricultural sector.

CRCs are an incorporated or unincorporated organisation, formed through collaborative partnerships between publicly funded researchers and end users. CRCs must comprise at least one Australian end-user (either from the private, public or community sector) and one Australian higher education institution (or research institute affiliated with a university).

Cooperative Research Centre

There are currently seven broad CRC sectors.

CRC for Biomarker Translation (CRC-BT) – The CRC-BT focuses on the development of diagnostic and therapeutic biomarkers for the treatment of cancer and autoimmune diseases. The CRC-BT is headquartered at La Trobe University, Bundoora, Victoria. CRC for Biomedical Imaging Development (CRC BID) – The primary aims of the CRC BID are to develop new and advanced imaging techniques and equipment for application in biomedicine; and to foster the growth of Australian expertise in biomedical imaging. The CRC BID is headquartered in Bundoora, Victoria.

Cancer Therapeutics CRC (CTx) – The focus of the CTx is working on the discovery and early development of small molecule drugs or enabling therapeutics for the treatment of cancer. Ctx is headquartered at the Walter and Eliza Hall Institute’s Biotechnology Centre in Bundoora, Victoria.

CRC for Mental Health – The CRC for Mental Health researches early detection and treatment of neurodegenerative diseases and psychoses. The CRC’s research includes areas such as Alzheimer’s and Parkinson’s Disease and psychoses such as schizophrenia and mood disorders.

CRC for Oral Health Science – The CRC for Oral Health Science brings together scientists, dentists, population health experts and manufacturers to find new and efficient ways of reducing the burden of oral disease in Australia. The CRC for Oral Health Science is headquartered at the Royal Dental Hospital, Carlton, Victoria.

CRC for Polymers – The research focus of the CRC for Polymers is on developing ‘functional’ (i.e. responsive to physical or biological stimuli) and higher value-added specialty polymers for emerging high growth opportunities. The Polymer CRC is headquartered in Notting Hill, Victoria. The HEARing CRC – The HEARing CRC brings together an internationally unique consortium dedicated to the common purpose of ‘creating sound value’ through research – to prevent and better remediate the lost productivity resulting from hearing loss in children and adults. The HEARing CRC is headquartered at the University of Melbourne, Parkville, Victoria.

News & opinion

Member Directory

BioMelbourne Network respectfully acknowledges the Traditional Custodians of the unceded lands and waters of Victoria: the Bunurong, Gunaikurnai and Wurundjeri peoples, on which the BioMelbourne Network and our Victorian members work, and as well as the lands and waters of our members further afield. We pay respect to their Elders past and present. As Australia’s first scientists, we acknowledge the significant contribution that they and other Aboriginal and Torres Strait Islander people have made and continue to make to the research and knowledge systems that inform our community and our sector.

We acknowledge that Aboriginal and Torres Strait Islander people continue to live in a spiritual and sacred relationship with this country and recognise our responsibility to continue to work towards reconciliation.

Copyright © BioMelbourne Network Network

• Privacy Policy

Website by Silver Lane Studio

Melbourne Clinical Trials

Participate in a clinical trial and get paid up to $600/day for your time

Australia’s largest Phase 1 clinical trial facility.

Located within Melbourne’s Alfred Research Alliance medical precinct, our 94-bed inpatient clinic (formerly known as the Centre for Clinical Studies) is Australia’s largest Phase 1 clinical trial facility.

We offer a variety of clinical trials in Melbourne at any time. These can include vaccine studies where there is no inpatient stay, shorter studies with 2-3 night stays, and some of up to a month or sometimes longer. Most studies also have at least 1 follow up outpatient visit.

Not only will you be reimbursed up to $600 per day for your time, but you can also help in the creation of new treatments for dozens of medical conditions that affect millions of people around Australia and the world .

Generally speaking, our Healthy Studies require participants that don’t have any health conditions. Our Patient Studies require participants who have a health conditions relating to the trial e.g. high cholesterol, asthma etc. You can view a selection of our studies below.

We have a constantly changing roster of studies, with new ones being added frequently. If you can't see one that works for you at the moment, please register your interest or give us a call on 1800 243 733 and we'll help find the right study for you.

日本人の臨床試験への参加者を募集しています。/ We are looking for Japanese people to participate in clinical studies

• Melbourne: Current Studies
• Eligibility
• Overnight stays
• Outpatient visits
• Biological Sex Male or Female
• Age 18-55 years old
• BMI 18 - 32kg/m²
• Asthma Diagnosed with mild – moderate asthma for at least 12 months
• Medical History No other significant medical history
• Smoking History Non-smokers for at least 12 months
• Medical History No significant medical history
• Medication Not taking any medication
• Smoking History Non-smokers only
• Contraception Hormonal contraception is not permitted
• Biological Sex Healthy males and females
• Age 18 - 55 years old
• BMI 18 - 32 kg/m²
• Medications Not taking any prescription medication (hormonal contraception is permitted)
• Smoking History Non-smokers
• BMI 18.5 - 32kg/m²
• Medication Not taking any prescription medication (Hormonal contraceptives NOT permitted)
• Contraception Requirements Non-hormonal IUD permitted ONLY as acceptable contraception method OR post-menopausal/surgically sterile (same sex with no contraception also accepted)
• Covid-19 Vaccinations Primary course of approved COVID-19 Vaccine required
• Biological Sex Female & Male
• BMI 18-35 kg/m2
• Medication Certain stable medical conditions may be permitted
• Smoking History Non-smokers OR smoking less than ≤10 cigarettes per/week
• Age 18-60 years old
• Weight More than 45kg for females, and more than 50kg for males
• Medication Not taking any prescription medication (except for hormonal contraception)
• Smoking History Non-smokers OR smoking no more than <2 cigarettes per/month
• Biological Sex Healthy Males & Females
• Weight >45kg
• Medications Not taking any prescription medication (except for hormonal contraception)
• Medical History Nothing significant
• Biological Sex Female
• Age 18-65 years old
• Weight Weigh a minimum of >45kg
• Medication Not taking any prescription medication
• Smoking History Non-smokers or smoking less than 10 cigarettes/week
• Contraception Guide Hormonal contraception is NOT permitted if being used for contraception
• Biological Sex Males & Females of non-childbearing potential
• BMI 18-32 kg/m2
• Biological Sex Caucasian Males (Defined as European, Middle Eastern or North African descent)
• BMI 19-32 kg/m2
• Weight Weigh at least >50kg+
• Medication Not taking any prescription medication (Hormonal contraceptives are permitted)
• Smoking History Non-smokers or smoking <5 cigarettes per week
• Weight Weigh more than 50kg
• Medication Not taking any prescription medication (Hormonal contraception accepted)
• Biological Sex Healthy Caucasian males and females (Defined as European, Middle Eastern or North African descent)
• Age 18 - 50 years old
• Body Weight Males: ≥ 50 kg Females: ≥ 45 kg
• Medications Not taking any prescription medication (hormonal contraception is allowed)
• Age 18 – 65 years old
• Weight <120kg
• Medical History Diagnosed with mild – moderate asthma. Otherwise, no other significant history
• Medications ABA, ICS/LABA and LTRA medications to treat asthma are allowed - Must not taking any other prescription medication
• Age 18-70 years old
• BMI 18 - 35kg/m²
• Weight between 60kg - 120Kg
• Biological sex Male or Female
• Age 18-55 years
• Smoking History Non-smokers or light smokers (<5 cigarettes/week) in past 90 days

While you are in the clinic we provide:

Recreational spaces, full catering, bedside monitoring, the best of australian healthcare.

To learn more about what it's like to participate in one of our Melbourne clinical trials, follow the Participant Journey or read our FAQs .

我们正在寻找中国人参与临床研究 / We are looking for Chinese people to participate in clinical studies

Check your eligibility in 2 minutes

© Copyright Nucleus Network

• Skip to content
• Skip to navigation

• News & Events
• Current page: Melbourne’s new incubator offers biotech startups an added advantage

Melbourne’s new incubator offers biotech startups an added advantage

Breakthrough Victoria in collaboration with world-leading biotech and health sciences company, CSL , the Walter and Eliza Hall Institute of Medical Research and the University of Melbourne have formed a consortium to accelerate biotech commercialisation across the state.

Valued at $95 million, the new incubator will have capacity to host up to 40 biotech start-ups at a time and provide unparalleled access to industry expertise, academic and clinical facilities and infrastructure.

The incubator is the first project to receive an investment from the $2 billion Breakthrough Victoria Fund which will help local start-ups overcome barriers to turning ideas into commercial outcomes by providing vital access to sophisticated technology platforms and expert technical support.

Located within the Parkville Biomedical Precinct, the incubator will capitalise on the infrastructure investments made in the Parkville National Employment and Innovation Cluster (NEIC), which includes 30 world-class hospitals, medical research institutes, cooperative research centres and universities.

Breakthrough Victoria is actively seeking investment opportunities to transform innovations in key industry sectors such as health and life sciences, agri-food, advanced manufacturing, clean economy and digital technologies into real world applications.

Victoria’s medical research sector supports more than 30,000 jobs across institutes, universities and industry, with more than 40 per cent of Australian-based biotechnology and medical technology companies calling Melbourne home.

To explore opportunities for collaborating with Melbourne’s biotechnology sector or investing in the sector, contact us .

ALWAYS LIVE

8th international conference on quantum techniques in machine learning, boxing day test, change language, what to read next.

• Invest Victoria +61 3 9651 8100
• Follow us on X
• Join us on LinkedIn
• Why Melbourne
• Opportunities
• How we can help
• Freedom of information
• Accessibility